Kisspeptin-54 is a naturally occurring, amidated 54-residue peptide that activates reproductive signaling through KISS1R. Researchers have used the synthetic peptide to stimulate gonadotropins, trigger final egg maturation during specialist IVF care and examine brain responses to sexual stimuli. Its human evidence reaches different points along that biological chain: hormone release, mature oocytes, pregnancies and acute neural responses. The preparation, population and measured outcome determine what each result contributes.
Overview
Kisspeptin-54 was first isolated from human placenta as the peptide metastin, a product of the KISS1 gene. The original work investigated receptor binding and cancer-cell behavior. Subsequent reproductive studies established its place in the system that controls GnRH and pituitary hormone release. The discovery name records that history; it does not establish a cancer treatment. Ohtaki and colleagues (2001).
Molecular profile
Forms and derivatives
Metastin
The original name for the amidated 54-residue human peptide isolated from placenta.
Kisspeptin-10, -13 and -14
Related family members share the amidated receptor-active C-terminal region. The shorter KP10 peptide has its own physiological study record.
The peptide shares an amidated C-terminal receptor-active sequence with kisspeptin-10. Kisspeptin-13 and -14 are related endogenous forms. Additional residues can affect exposure and response, so a clinical report needs its actual length and route identified. Kotani and colleagues (2001).
Uses and research areas
Reproductive research includes hypothalamic amenorrhea, where upstream hormonal activity is suppressed, and final oocyte maturation during IVF after controlled ovarian stimulation. Kisspeptin-54's action upstream of the pituitary offers a way to recruit an endogenous LH surge, which can help an already-developed follicle complete maturation. This specific step sits inside a larger clinical process involving stimulation, egg retrieval, fertilization, embryo transfer and follow-up. Jayasena and colleagues (2014).
A second research direction examines sexual and attraction processing in people with hypoactive sexual desire disorder. Brief crossover experiments measured functional brain imaging, psychometric responses and, in men, penile tumescence during visual sexual stimuli. These laboratory outcomes help identify biological effects that longer symptom trials could evaluate. Thurston and colleagues (2022); Mills and colleagues (2023).
Mechanism of action
Kisspeptin activates KISS1R on the pathway stimulating GnRH release. GnRH then acts at the pituitary to release LH and FSH, which influence ovaries and testes. The resulting hormone response depends on the axis's sensitivity and the available GnRH response. In IVF research, the investigators aim to use this cascade to support final oocyte maturation after the follicles have been developed through the preceding treatment. Jayasena and colleagues (2014).
The pathway is sensitive to the surrounding hormonal state. Jayasena's form-comparison experiments found differing responses to the short and long peptides during the follicular phase. Repeated stimulation can also reduce later responses, a phenomenon called tachyphylaxis. These properties connect the peptide's receptor action with the practical questions of cycle phase, duration and clinical population. Jayasena and colleagues (2011); amenorrhea study (2009).
Pharmacokinetics
Dhillo and colleagues infused kisspeptin-54 into a vein in six healthy men and compared their hormone levels with those measured after saline. After the infusion, blood measurements from the same six men gave an average disappearance half-life of 27.6 minutes, with a standard error of 1.1 minutes. The antibody-based test also recognized the shorter kisspeptin-14 and kisspeptin-10 forms, so it could not isolate the amount of complete kisspeptin-54. Dhillo and colleagues (2005).
A concentration curve is therefore omitted. The plasma estimate describes the tested intravenous experiment; it cannot define the duration of a subcutaneous IVF-trigger response or an effect in the brain. The subsequent LH surge represents a downstream biological process with its own timing.
Research findings
Initial stimulation followed by reduced response in amenorrhea
A randomized study assigned five women with hypothalamic amenorrhea to kisspeptin-54 and five to saline over two weeks. Gonadotropins rose strongly at first, then the LH and FSH responses diminished by the final assessment. Responsiveness to GnRH remained, and the study found no significant improvement in the measured LH pulsatility or ultrasound markers of reproductive activity. The result locates the adaptation within this experimental setting and explains why an initial hormone rise alone cannot predict sustained reproductive recovery. Jayasena and colleagues (2009).
Oocyte maturation within IVF care
The initial IVF proof-of-concept study treated 53 women after conventional ovarian stimulation. Mature eggs were obtained in 51; 49 proceeded to fertilization and embryo transfer. Clinical pregnancies occurred in 12 of the 53 treated women, and live births were documented. The study established feasibility across several linked steps, with no established-trigger control that could determine comparative live-birth success. Jayasena and colleagues (2014).
A later study involved 60 women at high risk of ovarian hyperstimulation syndrome. Oocyte maturation occurred in 57, and the reported live-birth rate was 45% per embryo transfer among 51 transfers. No moderate, severe or critical OHSS was observed. Mild cases still occurred, and the study compared assigned kisspeptin groups rather than an established trigger. The different egg, transfer and birth denominators represent successive selection steps in the IVF process. Abbara and colleagues (2015).
A 62-woman randomized study then compared additional kisspeptin-54 with saline after everyone had received the initial kisspeptin trigger. More participants reached the specified mature-oocyte-yield threshold with the additional exposure. This design tests refinement of a kisspeptin-based trigger; it does not compare kisspeptin against no trigger or establish live-birth superiority over standard care. Abbara and colleagues (2017).
Sexual-brain processing during brief experiments
Thurston's study randomized 40 women with HSDD, with 32 completing both kisspeptin and placebo visits. Kisspeptin-54 altered task-related activation and deactivation in several brain regions, with some changes correlated with distress or sexual-aversion measurements. A separate study randomized 37 men and analyzed 32 who completed both visits. It found altered sexual-stimulus brain responses and increased penile tumescence. Both studies measured acute responses during monitored laboratory exposure. The experiments provide a rationale for future therapeutic trials while leaving sustained symptom benefit and repeated-use safety unresolved. Thurston and colleagues (2022); Mills and colleagues (2023).
Safety and tolerability
The IVF investigations occurred within specialist care with ovarian assessment and monitoring for OHSS. The 60-woman high-risk study observed no moderate or worse cases, but sixty participants provide limited information about uncommon complications. The later randomized refinement study reported a moderate early OHSS case in the additional-placebo group and a mild late case in the additional-kisspeptin group. These observations support continued investigation of safety alongside the maturation results. Abbara 2015; Abbara 2017.
The women’s imaging study reported no adverse effects during its brief experimental exposures. That finding describes the laboratory study's observation window. The clinical applications reviewed here remain investigational, with larger comparative trials needed to characterize prolonged use, specific patient groups and reproductive outcomes. Thurston and colleagues (2022).
What the research means
Kisspeptin-54 has moved beyond a hormone-response probe to proof-of-concept use at a defined step within IVF. Pregnancies and live births after the experimental trigger are meaningful observations; the outstanding comparison concerns how that strategy performs against established triggers in appropriate populations, including live-birth outcomes and uncommon harms.
The sexual-processing work follows a different path. Brain imaging and tumescence show responses to a controlled stimulus at a study visit, while durable relief of HSDD requires sustained patient-reported outcomes and longer tolerability assessment. Keeping those two research programs visible prevents reproductive endocrine activity from becoming a catch-all claim about fertility or desire.
FAQs
Have live births occurred after a kisspeptin-54 IVF trigger?
Yes. Live births were documented in the initial proof-of-concept program, and the 60-woman high-risk study reported 45% live births per transfer among 51 transfers. The comparison groups were assigned kisspeptin exposures, so comparative live-birth effectiveness against established triggers remains unresolved. Abbara and colleagues.
Does the OHSS finding show the complication is eliminated?
The 60-woman study observed no moderate or worse cases; mild cases occurred. Uncommon complications and relative safety require a larger comparison, and the later refinement study did report a moderate early case. 2015 study; 2017 trial.
Do the imaging studies establish a lasting desire treatment?
Participants received kisspeptin-54 and placebo on separate laboratory visits while viewing sexual stimuli. Researchers measured brain activity and, in the male study, swelling of erectile tissue. These immediate responses do not establish that repeated treatment produces lasting relief of low desire; that requires longer symptom and safety follow-up.
What does desensitization mean here?
In women with hypothalamic amenorrhea, later hormone responses became smaller during the tested repeated-exposure study. The population, form and exposure pattern are part of that result; other kisspeptin experiments address different settings. Jayasena and colleagues.
Comparisons and related reading
Kisspeptin-10 clarifies what the shared receptor-active region can do in small endocrine experiments. Bremelanotide provides a useful example of randomized treatment trials with desire and distress endpoints, and the receptor explainer helps trace the upstream-to-downstream chain used in IVF research.
References
A shared receptor-binding region did not produce identical responses across hormonal contexts.
An initial strong hormone response did not remain strong throughout repeated stimulation.
After standard ovarian stimulation, 53 women received kisspeptin-54 as the final egg-maturation trigger. Mature eggs were obtained in 51, with pregnancies and live births reported; no standard-trigger group established comparative success.
Among 60 women at high risk of ovarian hyperstimulation syndrome, 57 had mature eggs after a kisspeptin-54 trigger. The study observed mild OHSS but no moderate or worse cases, and compared kisspeptin regimens rather than a standard trigger.
More women reached the specified egg-yield threshold with additional exposure.
Brain processing changed during a brief laboratory experiment.
A short experiment detected neural and physiological responses.
The placenta-derived amidated 54-residue peptide establishes metastin identity and the original receptor-ligand discovery.
Identifies related endogenous peptide lengths and receptor signaling in the original ligand-discovery experiments.
The original analogue experiment states the amidated human C-terminal decapeptide sequence.
- Dhillo WS, Chaudhri OB, Patterson M, Thompson EL, Murphy KG, Badman MK, McGowan BM, Amber V, Patel S, Ghatei MA, Bloom SR. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. Journal of Clinical Endocrinology and Metabolism. 2005;90(12):6609–6615. DOI: 10.1210/jc.2005-1468. · researchgate.net
The initial male physiology study documents hormone stimulation and a reported plasma half-life after intravenous exposure.
Glossary
- Oocyte
- An egg cell; mature oocytes can proceed to fertilization in an IVF laboratory.
- OHSS
- Ovarian hyperstimulation syndrome, a complication of ovarian stimulation that can involve enlarged ovaries, fluid shifts and severe illness.
- IVF trigger
- The final maturation stimulus used before egg retrieval within an in vitro fertilization cycle.
- Tachyphylaxis
- A reduction in response during repeated or continuing exposure.
- Tumescence
- Swelling of erectile tissue, used as a physiological arousal measurement in the male imaging study.